THURSDAY, Feb. 19 (HealthDay News) — A powerful clot-busting drug approved by the U.S. Food and Drug Administration for use in stroke patients in 1996 is still rarely used in Medicare patients, new research shows.
Only 2.4 percent of the more than 495,000 admissions for stroke at the 4,750 hospitals evaluated were given tissue plasminogen activator (tPA), said study author Dr. Dawn Kleindorfer, an associate professor of neurology at the University Read the rest of this entry »

will
review a new type of drug designed to keep blood clots from forming, according
to a meeting notice set for publication in the Federal Register.
The drug, rivaroxaban, from
(JNJ), is a new type of drug that targets an enzyme known as Factor Xa
that’s involved in the blood-clotting process. Other anti-clotting agents
currently on the market like Plavix, by
Bristol-Myers Squibb Co.
(SNY), and aspirin work through a different mechanism and Read the rest of this entry »

WASHINGTON, Jan 7 (Reuters) – Two proposed therapies to
treat rare blood disorders appear safe and effective for U.S.
approval, Food and Drug Administration staff reviewers said in
documents released on Wednesday.
CSL.AX
GTCB.O
) anti-clotting drug Atryn both
appeared to work in company studies, the FDA staff said in
reports prepared for an advisory panel that meets on Friday.
Both products would need further study after they begin
sales, Read the rest of this entry »

FRIDAY, Feb. 20 (HealthDay News) — Gender definitely makes a difference when it comes to stroke, new research shows.
Not only can stroke show itself in slightly different fashion in women than it typically does in men, but women also don’t get the gold standard of treatment for stroke as often as men do.
Those are two of several findings on women and stroke that were presented Thursday during a news conference at the International Stroke Conference Read the rest of this entry »

(Adds company comments, share price, additional product
details)
WASHINGTON, Jan 7 (Reuters) – Two proposed therapies to
treat rare blood disorders appear safe and effective for U.S.
approval, including one made from genetically engineered goats,
Food and Drug Administration staff reviewers said in documents
released on Wednesday.
GTCB.O
) anti-clotting drug Atryn,
made from human proteins inserted into goat milk, and CSL Ltd’s
(
CSL.AX
Read the rest of this entry »

jpmorgan chase finance summer analyst program   the finance organization provides an ideal opportunity for… regulators work with finance technology to establish… .
de.
hours in any combination of the following fields: accounting, business, finance, law, contracts, purchasing, economics, industrial management, marketing… .
ak.
e-verify participant (pdf 626 kb) right to work (pdf 1000 kb)

assistant finance director maniilaq health center Read the rest of this entry »

Celgene, FDA: Doctors Should Look For Alternatives To Blood Clot Drug
Posted on: Thursday, 1 January 2009, 15:42 CST
The FDA posted a letter to its Web site on Wednesday from Celgene Corp. warning users of blood-clot busting drug Innohep that new findings suggest the drug may lead to death in the elderly.
The letter urges doctors to suggest alternative drugs for patients with a blood clot condition known as deep vein thrombosis due to newly-reported Read the rest of this entry »

Drug, stent makers collaborate on anti-clot study
By LINDA A. JOHNSON –
TRENTON, N.J. (AP) — Several competing drug and medical device makers are starting an international collaboration to find out the best way to prevent potentially deadly blood clots from forming in heart patients who have artery-opening stents implanted.
At issue in the study, which also involves academic researchers and federal regulators, is how long patients Read the rest of this entry »

(Adds details, background)
NEW YORK, Dec 31 (Reuters) – A U.S. Food and Drug
Administration advisory panel will review Eli Lilly (
LLY.N
4568.T
) blood-clot preventer prasugrel, the
drugmakers said on Wednesday, adding a new hurdle for approval
of the potential blockbuster medicine.
The FDA’s cardiovascular and renal drugs committee will
review prasugrel on Feb. 3, the companies said, confirming
speculation that the medicine would require Read the rest of this entry »

an organization in their search for a finance director. the finance director will be responsible for… cash management

the finance director will work… .
al.
is seeking a highly qualified candidate to lead our finance and
accounting department. director of finance and accounting experience with dcaa, dcma and dfas… .
al.
experience: exceptional experience.
organic is all about the exceptional. we are a leading digital communications agency Read the rest of this entry »